3839 (3839) Fair Value & Analysis

Healthcare · Market cap HK$2.1B

3 3839 3839 · HK

PriceHK$8.50

Fair ValueHK$2.58

Upside-69.6%

Quality66/100

Watch 3839 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$1.71 – HK$3.23

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −7.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.75 – HK$9.85 · fair‑value band HK$1.71 – HK$3.23 · the HK$8.50 price screens above the HK$2.58 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3839 (3839) currently trades at HK$8.50, while our model-based Fair Value estimate is HK$2.58 — implying the stock looks roughly 69.6% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 3839 generated revenue of HK$470M at a net margin of 6.4%. Revenue declined 40.0% year over year. It earns a return on equity of 11.5%. Net debt stands at HK$7.7M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$470M

Revenue growth (YoY) -40.0%

Net margin 6.4%

Return on equity 11.5%

Free cash flow HK$28.0M FY2025

P/E ratio 8.9

More key figures

Operating margin 7.3%

EPS (TTM) HK$0.6759

EPS growth (YoY) +23.3%

Net debt HK$7.7M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3839 reported revenue of HK$537M in FY2025 versus HK$142M in FY2021, a compound +39.3%/yr. Reported net income was HK$32.1M in FY2025, compounding +13.2%/yr from FY2021.

Revenue +39.3%/yr

FY21 HK$142M

FY22 HK$159M

FY23 HK$174M

FY24 HK$308M

FY25 HK$537M

Net income +13.2%/yr

FY21 HK$19.6M

FY22 −HK$6.7M

FY23 HK$2.6M

FY24 HK$11.2M

FY25 HK$32.1M

Is 3839 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3839 (3839) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.58 versus a price of HK$8.50 — about −70% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 3839?

Our model-based fair value for 3839 is HK$2.58 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$8.50.

What is the quality score of 3839?

3839 has a Quality Score of 66/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3839 (3839)?

3839 reported trailing-twelve-month revenue of about HK$470M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3839?

The net profit margin of 3839 is about 6.4%, meaning it keeps roughly 6.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.